The Art of Seeing Around Corners: James Richman’s Predictions for the Next Decade of Medtech
James Richman, the investor-turned-CEO known for his...
23andMe Bankruptcy Shakes Biotech Sector as Early Warning Signs Go Unheeded
The recent bankruptcy filing of 23andMe has sent ripples...